Ads by Google

Cancer Treatment

FDA approves Inlyta for treating advanced kidney cancer

2012-01-28 15:36
kidney cancer, renal cell carcinoma, Inlyta, axtinib, Pfizer, cancer treatment

On January 27, The U.S. Food and Drug Administration (FDA) announced that it had approved Inlyta (axitinib), manufactured by Pfizer, Inc., for the treatment of patients with advanced renal cell carcinoma (kidney cancer) who have not responded to other medical treatments. Inlyta works by blocking certain proteins, known as kinases, which play a role in tumor growth and cancer progression. Inlyta is an oral medication that is taken twice daily.

conditions: 
Latest News: 
Health and Wellness: 

Pages